Comparative Pharmacology
Head-to-head clinical analysis: OCUSULF 10 versus RAXAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OCUSULF 10 versus RAXAR.
OCUSULF-10 vs RAXAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide sodium is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and exerting bacteriostatic effects.
RAXAR (revumenib) is a selective inhibitor of the menin-KMT2A protein-protein interaction. By binding to menin, it blocks the interaction with KMT2A (MLL1), thereby disrupting the transcription of oncogenic genes such as HOXA9 and MEIS1, leading to differentiation and apoptosis of leukemic cells.
Instill 1 drop into the affected eye(s) every 4 hours while awake.
Subcutaneous injection: 200 mg once daily, irrespective of timing of meals.
None Documented
None Documented
1.5–2.5 hours (terminal) in adults; prolonged to 3–5 hours in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 25 hours).
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites and unchanged drug.
Primarily hepatic metabolism; renal excretion of unchanged drug <5%; biliary/fecal elimination as metabolites accounts for >90% of total clearance.
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic